
## Xue Han

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7834/publications.pdf Version: 2024-02-01



Χήε Ηλη

#	Article	IF	CITATIONS
1	Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391.	8.2	1,112
2	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 2019, 25, 656-666.	30.7	461
3	Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity. Journal of Clinical Investigation, 2014, 124, 1966-1975.	8.2	227
4	PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine, 2019, 11, .	12.4	90
5	A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery, 2021, 11, 1700-1715.	9.4	86
6	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology, 2021, 23, 1922-1935.	1.2	33
7	Structural insight into T cell coinhibition by PD-1H (VISTA). Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1648-1657.	7.1	29
8	Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. International Review of Cell and Molecular Biology, 2019, 342, 1-25.	3.2	22
9	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports, 2021, 11, 13482.	3.3	13
10	The CD8α–PILRα interaction maintains CD8 <sup>+</sup> T cell quiescence. Science, 2022, 376, 996-1001.	12.6	9